Edwards SAPIEN 3 PPI Registry

计划入组 1,000 人 · 首次发布于 2018 年 4 月 13 日

Prospective Arm of Conduct - Edwards SAPIEN3 PPI Registry

计划入组 300 人 · 首次发布于 2018 年 10 月 23 日

Edwards SAPIEN-3 Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation

计划入组 56 人 · 首次发布于 2013 年 11 月 13 日

Edwards Syndrome (Trisomy 18) therapeutics(Elixirgen therapeutics)

DMARDs

SRPIN-340

Edwards Lifesciences LLC

United States

EDWARDS PHARMACEUTICALS, INC.

United States

EDWARDS LIFESCIENCES JAPAN LLC

Japan

FDA Approves Edwards' Sapien M3 as First Transseptal Mitral Valve Replacement System

Edwards Lifesciences' SAPIEN 3 RESILIA Valve Shows Strong One-Year Outcomes in TAVI Trial

Boston Scientific's Acurate neo2 TAVR Fails to Meet Primary Endpoint in IDE Trial